The use of isoform-selective PI3K inhibitors like alpelisib (BYL719), which is an oral isoform-selective PI3Ki targeting the p110α isoform of wild-type PI3Kα yet to be approved by FDA (FDA Approves Alpelisib for Metastatic Breast Cancer. Here, PIK3CD is linked to breast carcinoma.